Free Trial
→ Is Elon's empire crumbling? (From Brownstone Research) (Ad)
NASDAQ:XCUR

Exicure 6/27/2025 Earnings Report

Exicure logo
$7.45 +0.09 (+1.22%)
Closing price 03:58 PM Eastern
Extended Trading
$7.42 -0.03 (-0.35%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Exicure EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
6/27/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
August 4, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250804787056/en/exicure-inc.-nasdaq-xcur-regains-compliance-with-nasdaq-filing-requirements/
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 417.4%
August 4, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30254890
Sell this, buy that
What you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strategy: Sell This, Buy That. In his newest presentation, Eric reveals 7 new trade ideas—pairing overhyped, vulnerable stocks with lesser-known opportunities showing real upside. These contrarian picks come from the same approach that helped him beat Wall Street legends 10-to-1 in Portfolios with Purpose.
August 8 at 2:00 AM  |  InvestorPlace (Ad)
Stocks to Watch: Exicure, TTEC
August 3, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/stocks-to-watch-exicure-ttec-d2f1094c
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
August 1, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250801325070/en/Exicure-Completes-the-Last-Patient-Last-Visit-in-Phase-2-Study-of-GPC-100-for-Stem-Cell-Mobilization-in-Multiple-Myeloma-Patients-Undergoing-Autologous-Transplant/
XCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatch
July 19, 2025  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/xcur/financials/cash-flow
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles